Form 4 for CORT CORCEPT THERAPEUTICS INC
Accepted 2026-06-03 19:20:22 ET · period of report 2026-06-01 · accession 0001193125-26-256011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-03 19:20 | 2026-06-01 | CORT | Mokari Atabak | CFO | M - OptEx | $19.26 | +40.0K | 55.3K | +262% | +$770.4K |
| DT | 2026-06-03 19:20 | 2026-06-01 | CORT | Mokari Atabak | CFO | S - Sale+OE | $70.00 | -40.0K | 15.3K | -72% | -$2.80M |
| DMT | 2026-06-03 19:20 | 2026-06-01 | CORT | Mokari Atabak | CFO | A - Grant | $35.22 | +1,268 | 16.5K | +8% | +$44.7K |
| DT | 2026-06-03 19:20 | 2026-06-02 | CORT | Mokari Atabak | CFO | F - Tax | $70.44 | -395 | 16.1K | -2% | -$27.8K |
| DT | 2026-06-03 19:20 | 2026-06-01 | CORT | Mokari Atabak | CFO | M - OptEx | $0.00 | -40.0K | 60.0K | -40% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-01 | M | A | 40,000 | $19.26 | 55,257 | D | — | — | (F1) Includes 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 2 | Common | Common Stock | 2026-06-01 | S | D | 40,000 | $70.00 | 15,257 | D | — | — | (F2) This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction. (F3) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.00 to $70.01 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. (F1) Includes 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 3 | Common | Common Stock | 2026-06-01 | A | A | 634 | $70.44 | 15,891 | D | — | — | (F4) The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026. (F5) In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. (F1) Includes 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 4 | Common | Common Stock | 2026-06-01 | A | A | 634 | $0.00 | 16,525 | D | — | — | (F6) Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. (F1) Includes 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 5 | Common | Common Stock | 2026-06-02 | F | D | 395 | $70.44 | 16,130 | D | — | — | (F7) These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. (F8) The closing price on June 1, 2026 was used to calculate the withholding obligation. (F9) Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 6 | Derivative | Stock option (right to buy) | 2026-06-01 | M | D | 40,000 | $0.00 | 60,000 | D | $19.26 · — to 2032-02-02 | 40,000 Common Stock | (F10) Fully exercisable. |